Brian J Lipworth

Quick facts

Marketed products

• Budesonide/formoterol and tiotropium · Respiratory/Pulmonology
  This combination reduces airway inflammation and constriction by combining a corticosteroid with two bronchodilators that work through different pathways.
• Fluticasone propionate 50 micrograms per actuation
• Oxymetazoline 0.05% w/v · Otolaryngology / Respiratory
  Oxymetazoline is an alpha-1 adrenergic agonist that constricts blood vessels in the nasal mucosa, reducing nasal congestion.
• oxymetazoline-fluticasone propionate · Otolaryngology/Rhinology
  This combination nasal spray uses a decongestant to reduce nasal swelling and a corticosteroid to suppress inflammatory responses in the nasal passages.
• placebo to levocetirizine · Allergy/Immunology
  Levocetirizine is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms.
• Placebo to Prazosin · Cardiovascular; Urology; Psychiatry (off-label)
  Prazosin is an alpha-1 adrenergic receptor antagonist that blocks norepinephrine signaling to reduce blood pressure and improve urinary symptoms.
• Seretide 250/placebo via Synchro-Breathe · Respiratory/Pulmonology
  Seretide combines fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Brian J Lipworth portfolio CI brief
• Brian J Lipworth pipeline updates RSS